Skip to main content
SpringerLink
Log in

Regional variation and adherence to guidelines for drug treatment of asthma

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Aims

To describe the utilization of antiasthmatic drugs in Sweden and to explore regional variations in drug utilization and adherence to guidelines for rational drug prescribing of antiasthmatics and their rationale.

Methods

Data on antiasthmatic drugs dispensed between July 2005 and December 2008 to all Swedish citizens aged between 18 and 44 years were obtained from the Swedish National Prescribed Drug Register. The period prevalence was determined by analyzing the number of users/1000 inhabitants, and the incidence by analyzing the number of new users after an 18-month drug-free wash-out period. Three drug-related indicators were used to assess the adherence to guidelines. All measures were analyzed by gender and region.

Results

A total of 161,000 patients were dispensed antiasthmatics in 2007, corresponding to a prevalence of 4 and 6% among men and women, respectively; the incidence rates were 2 and 3%, respectively. The total drug utilization and adherence to guidelines varied between regions. The total drug expenditures of antiastmatics were 258 million SEK (28 million euro), with fixed dose combinations accounting for 46% of the expenditure. No relation was found between models for allocating prescribing budgets or clear Drug and Therapeutics Committee recommendations and adherence to guidelines.

Conclusion

There are large regional variations in the utilization of antiasthmatics between Swedish regions, with substantial room for improvement in the adherence to guidelines. New methods of influencing physician behavior may be needed in the future to enhance adherence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

R03:

Respiratory system

R03A:

Adrenergics inhalants

R03AC:

Selective beta-2-adrenoreceptor agonists

R03AK:

Adrenergics and other drugs for obstructive airway diseases, combinations

R03BA:

Glucocorticoids

LABA:

Long-acting beta-2-adrenoceptor agonist

SABA:

Short-acting beta-2-agonists

References

  1. Burney PG, Luczynska C, Chinn S, Jarvis D (1994) The European community respiratory health survey. Eur Respir J 7(5):954–960

    CAS  PubMed  Google Scholar 

  2. Läkemedelsverket Medical Products Agency (2007) Farmakologisk behandling vid astma–2007. Tryckt version. 2007(18) Temanummer

  3. Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O'Byrne P et al (2007) GINA guidelines on asthma and beyond. Allergy 62(2):102–112

    Article  CAS  PubMed  Google Scholar 

  4. Henriksson F, Hjortsberg C, Rehnberg C (1999) Pharmaceutical expenditure in Sweden. Health Policy 47(2):125–144

    Article  CAS  PubMed  Google Scholar 

  5. Moise P, Docteur E (2007) OECD Health Working Papers No. 28. Pharmaceutical pricing and reimbursement in Sweden:13 September 2007. Available at: htttp://www.olis.oecd.org/olis/2007doc.nsf/FREDATCORPLOOK/NT00002E52/$ FILE/JTO3231887.PDF (assessed 2 Feb 2008)

  6. Socialstyrelsen (2008) Läkemedelsförsäljningen I Sverige—analys och prognos. Stockholm

  7. Socialstyrelsen (2007) Läkemedelsförsäljningen I Sverige—analys och prognos (September 2007). Stockholm

  8. Brodin H (1987) Regional variations in pharmaceutical consumption in Sweden. Linköping University, Linköping

    Google Scholar 

  9. Gerdtham UG, Hertzman P, Jonsson B, Boman G (1996) Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978 to 1991. Med Care 34(12):1188–1198

    Article  CAS  PubMed  Google Scholar 

  10. Haupt D, Krigsman K, Nilsson JL (2008) Medication persistence among patients with asthma/COPD drugs. Pharm World Sci 30(5):509–514

    Article  PubMed  Google Scholar 

  11. Krigsman K, Moen J, Nilsson JL, Ring L (2007) Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10-year period. J Clin Pharm Ther 32(6):603–611

    Article  CAS  PubMed  Google Scholar 

  12. Eckerlund I, Gerdtham UG (1998) Econometric analysis of variation in cesarean section rates. A cross-sectional study of 59 obstetrical departments in Sweden. Int J Technol Assess Health Care 14(4):774–787

    Article  CAS  PubMed  Google Scholar 

  13. Gillissen A (2007) Patients' adherence in asthma. J Physiol Pharmacol 58[Suppl 5]:205–222

    Google Scholar 

  14. Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njolstad I et al (2007) Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption—an individual-level prescription database study. BMC Clin Pharmacol 7:14

    Article  PubMed  Google Scholar 

  15. Wettermark B, Hammar N, MichaelFored C, Leimanis A, Otterblad Olausson P, Bergman U et al (2007) The new Swedish prescribed drug register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726–735

    Article  PubMed  Google Scholar 

  16. Arnlind MH, Nokela M, Rehnberg C, Jonsson EW (2006) The relationship between pharmaceutical costs, disease severity, and health-related quality of life in asthmatics in Swedish primary care. J Asthma 43(8):585–591

    Article  PubMed  Google Scholar 

  17. Sjöqvist F, Bergman U, Dahl ML (2002) eaDatcaSeWDI. Drug and therapeutics committees: a Swedish experience. WHO Drug Inf 16:207–213

    Google Scholar 

  18. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V (2008) Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 26(7):537–550

    Article  PubMed  Google Scholar 

  19. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL (2009) Swedish experience in ambulatory care with multifaceted national and regional drug reforms and initiatives: global relevance. Expert Review. Pharmacoeconomics Outcomes Res 9(1):65–83

    Article  Google Scholar 

  20. Anell A (2005) Swedish healthcare under pressure. Health Econ 14[Suppl 1]:S237–S254

    Article  PubMed  Google Scholar 

  21. Socialdepartementet (2005) Socialdepartementet förordning (2005:363) om läkemedelsregister hos Socialstyrelsen. Stockholm

  22. World Health Organization (2005) Guidelines for ATC classification an DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology. Available at: www.whocc.no. WHO, Oslo

  23. World Health Organization (2007) Guidelines for ATC classification and DDD assignment. WHO Collaborationg Center for Drug Statistics Methodology 2007: Available at: http://www.whocc.no/

  24. World Health Organization (2003) Introduction to drug utilisation research, NLM classification WB 330. WHO, Oslo

  25. Hallas J, Stovring H (2006) Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol 98(3):260–265

    Article  CAS  PubMed  Google Scholar 

  26. Bergstrom G, Karlberg I (2007) Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective. Health Policy 81(2-3):358–367

    Article  PubMed  Google Scholar 

  27. Jansson S, Anell A (2006) The impact of decentralised drug-budgets in Sweden—a survey of physicians' attitudes towards costs and cost-effectiveness. Health Policy 76(3):299–311

    Article  PubMed  Google Scholar 

  28. Haaijer-Ruskamp F, HHoven J, Mol P (2004) A conceptual framework for constructing prescribing quality indicators: a poroposal. DURQUIM: Drug Utilization Quality Indicator Meeting. WHO, Mechelen

  29. Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH (2005) Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13–15 May 2004). Eur J Clin Pharmacol 60(11):831–834

    Article  CAS  PubMed  Google Scholar 

  30. Socialstyrelsen (2003) Indikatorer för utvärdering av kvaliteten I äldres läkemedelsterapi—socialstyrelsens förslag. Stockholm

  31. Naturhistoriska riksmuseet (2007) Årets pollensäsong—nu börjar det! Available at: htwww.nrm.se/sv/menss/pressmeddelandessmeddelanden/200t spollensasongnuborjardet.1374.html

  32. Ehrs PO, Nokela M, Stallberg B, Hjemdahl P, Wikstrom Jonsson E (2006) Brief questionnaires for patient-reported outcomes in asthma: validation and usefulness in a primary care setting. Chest 129(4):925–932

    Article  PubMed  Google Scholar 

  33. Kamble S, Bharmal M (2009) Incremental direct expenditure of treating asthma in the United States. J Asthma 46(1):73–80

    Article  PubMed  Google Scholar 

  34. Läkemedelsverket (2002) Bakgrukumentation—akologisk ndling av astma (database on the Internet). Available at: http://www.lakemedelsverket.se/upload/Hälso-%20och%20sjukvård/behandlingsrek/bakg_dok/astma_bakgrund.pdf

  35. Osborne ML, Vollmer WM, Linton KL, Buist AS (1998) Characteristics of patients with asthma within a large HMO: a comparison by age and gender. Am J Respir Crit Care Med 157(1):123–128

    CAS  PubMed  Google Scholar 

  36. Weiner P, Magadle R, Massarwa F, Beckerman M, Berar-Yanay N (2002) Influence of gender and inspiratory muscle training on the perception of dyspnea in patients with asthma. Chest 122(1):197–201

    Article  PubMed  Google Scholar 

  37. Abraham B, Antó JM, Barreiro E, Bel EHD, Bousquet J, Castellsagud J, et al (2003) The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 22(3):470–477

    Google Scholar 

  38. Diette GB, Wu AW, Skinner EA, Markson L, Clark RD, McDonald RC et al (1999) Treatment patterns among adult patients with asthma: factors associated with overuse of inhaled beta-agonists and underuse of inhaled corticosteroids. Arch Intern Med 159(22):2697–2704

    Article  CAS  PubMed  Google Scholar 

  39. Cockcroft DW, Davis BE (2006) Airway hyperresponsiveness as a determinant of the early asthmatic response to inhaled allergen. J Asthma 43(3):175–178

    Article  CAS  PubMed  Google Scholar 

  40. Hasselgren M, Arne M, Lindahl A, Janson S, Lundback B (2001) Estimated prevalences of respiratory symptoms, asthma and chronic obstructive pulmonary disease related to detection rate in primary health care. Scand J Prim Health Care 19(1):54–57

    Article  CAS  PubMed  Google Scholar 

  41. Nilsson JLG, Haupt D, Krigsman K, Moen J (2009) Asthma/COPD drugs reflecting disease prevalence, patient adherence and persistence. Expert Review (serial on the Internet)

  42. Beasley R, Martinez FD, Hackshaw A, Rabe KF, Sterk PJ, Djukanovic R (2009) Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J 33(1):3–5

    Article  CAS  PubMed  Google Scholar 

  43. Cates CJ, Cates MJ, Lasserson TJ (2008) Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 4:CD006923

    PubMed  Google Scholar 

  44. GINA Guidelines. (2008) Pocket guide for asthma management and prevention 2008: Available at: http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=1562

  45. Ni CM, Greenstone IR, Ducharme FM (2005) Addition of inhaled long-acting beta2- agonists to inhaled steroids as first line therapy for persistent asthma in steroid- naive adults. Cochrane Database Syst Rev 2:CD005307

    PubMed  Google Scholar 

  46. Partridge MR, Fabbri LM, Chung KF (2000) Delivering effective asthma care—how do we implement asthma guidelines? Eur Respir J 15(2):235–237

    Article  CAS  PubMed  Google Scholar 

  47. Wiener-Ogilvie S, Huby G, Pinnock H, Gillies J, Sheikh A (2008) Practice organisational characteristics can impact on compliance with the BTS/SIGN asthma guideline: qualitative comparative case study in primary care. BMC Fam Pract 9:32

    Article  PubMed  Google Scholar 

  48. Eccles MP, Soutter J, Bateman DN, Campbell M, Smith JM (1996) Influences on prescribing in non-fundholding general practices. Br J Gen Pract 46(406):287–290

    CAS  PubMed  Google Scholar 

  49. Mansouri M, Lockyer J (2007) A meta-analysis of continuing medical education effectiveness. J Contin Educ Health Prof 27(1):6–15

    Article  PubMed  Google Scholar 

  50. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA (1998) Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. Br Med J 317(7156):465–468

    CAS  Google Scholar 

  51. Taylor DM, Auble TE, Calhoun WJ, Mosesso VN Jr (1999) Current outpatient management of asthma shows poor compliance with International Consensus Guidelines. Chest 116(6):1638–1645

    Article  CAS  PubMed  Google Scholar 

  52. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L et al (2004) Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 8(6):1–72

    Google Scholar 

  53. Brown MM, Brown GC, Sharma S, Hollands H, Smith AF (2001) Physician manpower and health care expenditures in the United States: a thirty-year perspective. J Health Care Finance 27(4):55–64

    CAS  PubMed  Google Scholar 

  54. Folland S, Goodman A, Stano M (eds) (2004) The ecoonomics of health and health care. Pearson Prentice Hall, Upper Saddle River

  55. Leonard C, Stordeur S, Roberfroid D (2009) Association between physician density and health care consumption: A systematic review of the evidence. Health Policy 91:121–34

    Google Scholar 

  56. Grol R, Grimshaw J (2003) From best evidence to best practice: effective implementation of change in patients' care. Lancet 362(9391):1225–1230

    Article  PubMed  Google Scholar 

  57. Grol R, Wensing M (2004) What drives change? Barriers to and incentives for achieving evidence-based practice. Med J Aust 180[Suppl]:S57–S60

    PubMed  Google Scholar 

  58. Wettermark B, Haglund K, Gustafsson LL, Persson PM, Bergman U (2005) A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists. Pharmacoepidemiol Drug Saf 14(8):579–588

    Article  PubMed  Google Scholar 

  59. Wisnivesky JP, Lorenzo J, Lyn-Cook R, Newman T, Aponte A, Kiefer E et al (2008) Barriers to adherence to asthma management guidelines among inner-city primary care providers. Ann Allergy Asthma Immunol 101(3):264–270

    Article  PubMed  Google Scholar 

  60. Cochrane GM, Horne R, Chanez P (1999) Compliance in asthma. Respir Med 93(11):763–769

    Article  CAS  PubMed  Google Scholar 

  61. Lindberg M, Ekstrom T, Moller M, Ahlner J (2001) Asthma care and factors affecting medication compliance: the patient's point of view. Int J Qual Health Care 13(5):375–383

    Article  CAS  PubMed  Google Scholar 

  62. Stallberg B, Nystrom Kronander U, Olsson P, Gottberg L, Ronmark E, Lundback B (2003) Living with asthma in Sweden–the ALMA study. Respir Med 97(7):835–843

    Article  CAS  PubMed  Google Scholar 

  63. Krigsman K, Melander A, Carlsten A, Ekedahl A, Nilsson JL (2007) Refill non-adherence to repeat prescriptions leads to treatment gaps or to high extra costs. Pharm World Sci 29(1):19–24

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful to Andrejs Leimanis, EpC, The National Board of Health and Welfare, and Anders Hansson and Bengt Sjöborg, Department of Drug Management and Informatics, Stockholm County Council, for their invaluable contributions with the data extractions. We also acknowledge Brian Godman for valuable comments on this manuscript. The study was supported by the Centre for Allergy Research at Karolinska Institutet.

Author information

Authors and Affiliations

  1. Centre for Allergy Research, Karolinska Institutet, SE-171 77, Stockholm, Sweden

    Marianne Heibert Arnlind, Mika Nokela & Eva Wikström Jonsson

  2. Medical Management Centre, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, SE-171 77, Stockholm, Sweden

    Marianne Heibert Arnlind & Clas Rehnberg

  3. Department of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital (Solna), SE-171 76, Stockholm, Sweden

    Mika Nokela, Paul Hjemdahl & Eva Wikström Jonsson

  4. Centre for Pharmacoepidemiology, Karolinska Institutet, Karolinska University Hospital, SE-171 76, Stockholm, Sweden

    Björn Wettermark

Authors
  1. Marianne Heibert Arnlind
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Björn Wettermark
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mika Nokela
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul Hjemdahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Clas Rehnberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eva Wikström Jonsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marianne Heibert Arnlind.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arnlind, M.H., Wettermark, B., Nokela, M. et al. Regional variation and adherence to guidelines for drug treatment of asthma. Eur J Clin Pharmacol 66, 187–198 (2010). https://doi.org/10.1007/s00228-009-0731-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-009-0731-7

Keywords

Search

Navigation